This review reinforces the critical importance of aggressive glycemic and blood pressure control, particularly with renin-angiotensin system blockers, to manage diabetic nephropathy.
No takes yet. Share an insight, caveat, or question.
Upholds glycemic control and RAS blockade as core management in diabetic nephropathy; extends molecular insights but leaves clinical translation open.
Caramori et al. (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: